Advance market commitment

Last updated

An advance market commitment (AMC) is a promise to buy or subsidise a product if it is successfully developed. AMCs are typically offered by governments or private foundations to encourage the development of vaccines or treatments. In exchange, pharmaceutical companies commit to providing doses at a fixed price. This funding mechanism is used when the cost of research and development is too high to be worthwhile for the private sector without a guarantee of a certain quantity of purchases.

Contents

The idea of advance market commitments was developed by economists in the 2000s. This idea was applied to finance the pneumococcal conjugate vaccine. During the Covid-19 crisis, the COVAX AMC provided 1.8 billion vaccine doses to 87 low and middle-income countries. [1] AMCs could be used to stimulate research on universal vaccines, which would contribute to pandemic preparedness. An AMC has also been launched for carbon-removal that meets certain technical specifications.

Description

In the case of vaccines, an advance market commitment is a contract between three types of parties: the sponsors, the recipient countries, and the firms. [2] The sponsors promise to largely subsidise vaccines that meet certain eligibility requirements, up to a fixed number of doses. For example, a global fund can guarantee to pay $14 out of $15 for the first 200 million doses of vaccines that have an efficacy of more than 70%. Countries benefiting from the vaccines agree to pay the remaining part of the price ($1 in the example). This small co-payment ensures that there is an actual demand for the vaccines. In return, the firms commit to provide further doses at a small price, close to the cost of production. In the example, the pharmaceutical companies which develop an eligible vaccine would benefit from the high $15 price for the first 200 million doses, but would have to provide all further doses at a low price, like $1 per dose. [2] This stipulation ensures that the product stays affordable for developing countries in the long run. [2]

While using a pull funding mechanism intended to supplement direct support for R&D (classified as push funding), AMC aims to navigate the challenge of selecting promising projects in advance amid conditions of asymmetric information. [3] This approach incentivizes successful vaccine development by offering financial rewards based on outcomes, thereby facilitating investment in research without the necessity to accurately predict project success from the outset.[ citation needed ]

Vaccine market distortions

AMC is designed to address immediate and long-term vaccine market distortions, implementing a price cap strategy to limit deadweight loss. By offering an additional amount (top-up price) over the marginal cost of the vaccine, it aims to stimulate more investment in R&D. This enhancement in R&D is crucial in response to a series of identified challenges: the restricted demand from low-income countries due to limited purchasing power, the occurrence of the free-rider problem where individuals benefit from herd immunity without being vaccinated, and the risk of political pressure to reduce vaccine prices, altogether leading to a hold-up problem where manufacturers may be cautious about investing in R&D due to concerns over recovering their costs. [3] AMC strives to address these issues by providing a financial incentive to develop vaccines that might otherwise be overlooked.[ citation needed ]

Origins of the idea

In 1998, Michael Kremer published an academic article on patent buyouts: he argued that governments could improve access to treatments by buying patents and placing them in the public domain. [4] Inspired by his experiences in Kenya, where he contracted malaria, he then proposed the idea of a "vaccine purchase commitment" to encourage research on neglected diseases. [5] [6] In 2001, a report of the United Kingdom mentioned that a potential global fund to fight HIV/AIDS, malaria, and tuberculosis could also make advance purchase commitments. [7] This idea continued to gain traction in 2004, when Michael Kremer and Rachel Glennerster published a book advocating for it. [6] It gained additional momentum in 2005 with the publication of a report by the Center for Global Development. [2] In 2006, the G8 was considering setting up an "advance market commitment", and this expression was used in an academic paper estimating the cost-effectiveness of the measure. [8]

Applications

Pneumococcal disease

Coverage increased faster for pneumococcal vaccines than for rotavirus vaccines, which did not benefit from an AMC. Pneumococcal and rotavirus vaccine coverage (Gavi and non-Gavi countries).png
Coverage increased faster for pneumococcal vaccines than for rotavirus vaccines, which did not benefit from an AMC.

The first advance market commitment was launched in 2009 by GAVI, the World bank, WHO, UNICEF, five national governments, and the Gates Foundation. [9] It targeted pneumococcal disease. According to a 2005 WHO estimate, at that time, pneumococcal disease killed 1.6 million people every year, mostly in the Global South. [10] The AMC sponsors provided $1.5 billion to subsidise vaccine doses, [9] at an initial $3.5 per dose. [11] In 2010, GSK and Pfizer each committed to supply 30 million doses each year. [3] In 2020, the Serum Institute of India started producing a third vaccine at $2 per dose. [12] [13] [14] The Gavi Pneumococcal Conjugate Vaccine AMC officially finished in 2020, with contracts with manufacturers lasting until 2029. [15]

In 2021, development consulting firm Dalberg published a report evaluating the impact of the AMC. [15] The report did not find evidence that the AMC sped up the creation of new vaccines. However, the AMC led manufacturers to develop multi-dose vials, which helped drive down cost per dose. Despite initial production delays, the number of doses distributed each year grew from 3 million in 2010 to 150 million in 2015. Recipient countries introduced pneumococcal conjugate vaccines faster than HPV, rotavirus and Hib vaccines, which did not benefit from an AMC. Overall, the Dalberg report found that the AMC was probably successful at increasing vaccination coverage, which led to saving more lives. [15] However, quantifying the effectiveness of the program is difficult because of the lack of a valid counterfactual. [3] [15]

The AMC was relatively ineffective at driving vaccine prices down. [15] Before the arrival of the vaccine of the Serum Institute of India, Médecins sans frontières criticised the AMC for providing excessive subsidies to GSK and Pfizer. [16] [17] [18]

COVID-19

A shipment of vaccines delivered to Vietnam as part of the COVAX AMC UNICEF-Covid-Impstoff-Lieferung nach Vietnam 2019.jpg
A shipment of vaccines delivered to Vietnam as part of the COVAX AMC

Pandemic preparedness

Carbon removal

In December 2021, an AMC for carbon-removal was first proposed in a Politico essay by economists Susan Athey, Rachel Glennerster, Christopher Snyder and Nan Ransohoff, the head of Stripe Climate. [19]

In April 2022, Stripe launched Frontier Climate, an AMC, "to buy an initial $925M of permanent carbon removal between 2022 and 2030." [20] Ransohoff, who leads the project, told The Atlantic that the carbon-removal market will probably need to reach $1 trillion per year. [21]

Comparison to other incentives

Related Research Articles

<span class="mw-page-title-main">Pfizer</span> American multinational pharmaceutical and biotechnology corporation

Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered at The Spiral in Manhattan, New York City. The company was established in 1849 in New York by two German entrepreneurs, Charles Pfizer (1824–1906) and his cousin Charles F. Erhart (1821–1891).

The Campaign for Access to Essential Medicines is an international campaign started by Médecins Sans Frontières (MSF) to increase the availability of essential medicines in developing countries. MSF often has difficulties treating patients because the medicines required are too expensive or are no longer produced. Sometimes, the only drugs available are highly toxic or ineffective, and they often have to resort to inadequate testing methods to diagnose patients.

<span class="mw-page-title-main">Pneumococcal conjugate vaccine</span> Vaccine against Strep pneumoniae

Pneumococcal conjugate vaccine is a pneumococcal vaccine made with the conjugate vaccine method and used to protect infants, young children, and adults against disease caused by the bacterium Streptococcus pneumoniae (pneumococcus). It contains purified capsular polysaccharide of pneumococcal serotypes conjugated to a carrier protein to improve antibody response compared to the pneumococcal polysaccharide vaccine. The World Health Organization (WHO) recommends the use of the conjugate vaccine in routine immunizations given to children.

<span class="mw-page-title-main">Michael Kremer</span> American economist and Nobel laureate (born 1964)

Michael Robert Kremer is an American development economist currently serving as University Professor in Economics at the University of Chicago and Director of the Development Innovation Lab at the Becker Friedman Institute for Research in Economics. Kremer formerly served as the Gates Professor of Developing Societies at Harvard University, a role he held from 2003 to 2020. In 2019, Kremer was jointly awarded the Nobel Memorial Prize in Economic Sciences, together with Esther Duflo and Abhijit Banerjee, "for their experimental approach to alleviating global poverty."

<span class="mw-page-title-main">Pneumococcal vaccine</span> Vaccine to prevent infection by the bacteria Stretococcus pneumoniae

Pneumococcal vaccines are vaccines against the bacterium Streptococcus pneumoniae. Their use can prevent some cases of pneumonia, meningitis, and sepsis. There are two types of pneumococcal vaccines: conjugate vaccines and polysaccharide vaccines. They are given by injection either into a muscle or just under the skin.

Maria Deloria Knoll is an expert in the fields of epidemiology, disease surveillance, vaccine trial conduct, and bio-statistics. She currently serves as associate director of Science at the International Vaccine Access Center (IVAC), an organization dedicated to accelerating global access to life-saving vaccines, at the Johns Hopkins Bloomberg School of Public Health in Baltimore, Maryland.

Lois Privor-Dumm is an expert in the field of vaccine introduction. She is especially recognized for her work with new vaccine introduction, which has included strategies to accelerate access in low and middle-income countries, policy research, advocacy, communications and large country introduction.

Orin Levine is an epidemiologist known for his work in the fields of international public health, child survival, and pneumonia. He is currently the director of vaccine delivery at the Bill & Melinda Gates Foundation in Seattle, US. In the past he was the executive director of the International Vaccine Access Center (IVAC), the co-chair of the Pneumococcal Awareness Council of Experts (PACE), and is a professor at The Johns Hopkins Bloomberg School of Public Health in the Department of International Health. He is also an adjunct assistant professor of epidemiology at The Rollins School of Public Health at Emory University in Atlanta. Additionally, he is currently president of the American Society of Tropical Medicine and Hygiene (ASTMH) Council on Global Health. He resides in Washington, D.C.

<span class="mw-page-title-main">Katherine O'Brien</span> Canadian-born pediatric physician (born 1963)

Katherine "Kate" L. O'Brien is a Canadian American pediatric infectious disease physician, epidemiologist, and vaccinologist who specializes in the areas of pneumococcal epidemiology, pneumococcal vaccine trials and impact studies, and surveillance for pneumococcal disease. She is also known as an expert in infectious diseases in American Indian populations. O’Brien is currently the Director of the World Health Organization's Department of Immunization, Vaccines and Biologicals.

Innovative financing refers to a range of non-traditional mechanisms to raise additional funds for development aid through "innovative" projects such as micro-contributions, taxes, public-private partnerships and market-based financial transactions.

<span class="mw-page-title-main">Pneumococcal Awareness Council of Experts</span>

The Pneumococcal Awareness Council of Experts (PACE) is a project of the Sabin Vaccine Institute and is composed of global experts in infectious diseases and vaccines. Established in December 2006, The Council seeks to raise awareness among policymakers and aims to secure global commitments to prevent pneumococcal disease, a leading infectious killer of children and adults worldwide. The Council works in collaboration and partnership with countries, NGOs, academia and industry.

<span class="mw-page-title-main">GAVI</span> Global health organization

GAVI, officially Gavi, the Vaccine Alliance is a public–private global health partnership with the goal of increasing access to immunization in poor countries. In 2016, Gavi channeled more than half of total donor assistance for health, and most donor assistance for immunization, by monetary measure.

<span class="mw-page-title-main">Coalition for Epidemic Preparedness Innovations</span> Public-private organization for vaccine development

The Coalition for Epidemic Preparedness Innovations (CEPI) is a foundation that takes donations from public, private, philanthropic, and civil society organisations, to finance independent research projects to develop vaccines against emerging infectious diseases (EID).

<span class="mw-page-title-main">Economics of vaccines</span>

Vaccine development and production is economically complex and prone to market failure. Many of the diseases most demanding a vaccine, including HIV, malaria and tuberculosis, exist principally in poor countries. Pharmaceutical firms and biotechnology companies have little incentive to develop vaccines for these diseases because there is little revenue potential. Even in more affluent countries, financial returns are usually minimal and the financial and other risks are great.

Mathuram Santosham is an Indian American physician who is Professor and Chair at the Johns Hopkins Bloomberg School of Public Health. Santosham is best known for his work on oral rehydration therapy and childhood vaccines, with a focus on supporting people from indigenous communities.

<span class="mw-page-title-main">COVAX</span> Initiative to provide COVID-19 vaccines

COVID-19 Vaccines Global Access, abbreviated as COVAX, is a worldwide initiative aimed at equitable access to COVID-19 vaccines directed by the GAVI vaccine alliance, the Coalition for Epidemic Preparedness Innovations (CEPI), and the World Health Organization (WHO), alongside key delivery partner UNICEF. It is one of the four pillars of the Access to COVID-19 Tools Accelerator, an initiative begun in April 2020 by the WHO, the European Commission, and the government of France as a response to the COVID-19 pandemic. COVAX coordinates international resources to enable low-to-middle-income countries equitable access to COVID-19 tests, therapies, and vaccines. UNICEF is the key delivery partner, leveraging its experience as the largest single vaccine buyer in the world and working on the procurement of COVID-19 vaccine doses, as well as logistics, country readiness and in-country delivery.

<span class="mw-page-title-main">Shabir Madhi</span> South African physician and professor

Shabir Ahmed Madhi, is a South African physician who is professor of vaccinology and director of the South African Medical Research Council Respiratory and Meningeal Pathogens Research Unit at the University of the Witwatersrand, and National Research Foundation/Department of Science and Technology Research Chair in Vaccine Preventable Diseases. In January 2021, he was appointed Dean of the Faculty of Health Sciences at the University of the Witwatersrand.

The TRIPS Agreement waiver is a joint intervention communication by South Africa and India to the TRIPS council of the World Trade Organization (WTO) on 2 October 2020.

Vaccine equity means ensuring that everyone in the world has equal access to vaccines. The importance of vaccine equity has been emphasized by researchers and public health experts during the COVID-19 pandemic but is relevant to other illnesses and vaccines as well. Historically, world-wide immunization campaigns have led to the eradication of smallpox and significantly reduced polio, measles, tuberculosis, diphtheria, whooping cough, and tetanus.

<span class="mw-page-title-main">Nina Schwalbe</span> American public health researcher

Nina Schwalbe is an American public health researcher who is the founder of Spark Street Advisors, a public health think tank based in New York City. Schwalbe specializes in vaccines. She has previously worked at Gavi, UNICEF and USAID.

References

  1. ↑ "COVID-19 Market Dashboard | UNICEF Supply Division". www.unicef.org. Retrieved 2024-01-31.
  2. 1 2 3 4 "Making Markets for Vaccines: Ideas to Action". Center For Global Development. Retrieved 2023-06-23.
  3. 1 2 3 4 Kremer, Michael; Levin, Jonathan; Snyder, Christopher M. (2020-05-01). "Advance Market Commitments: Insights from Theory and Experience". AEA Papers and Proceedings. 110: 269–273. doi:10.1257/pandp.20201017. ISSN   2574-0768.
  4. ↑ Kremer, Michael (1998). "Patent Buyouts: A Mechanism for Encouraging Innovation". The Quarterly Journal of Economics. 113 (4): 1137–1167. doi:10.1162/003355398555865. ISSN   0033-5533. JSTOR   2586977. S2CID   31023203.
  5. ↑ Kremer, Michael (January 2000). "Creating Markets for New Vaccines. Part I: Rationale". Innovation Policy and the Economy. 1: 35–72. doi:10.1086/ipe.1.25056141. ISSN   1531-3468. S2CID   153622261.
  6. 1 2 Kremer, Michael; Glennerster, Rachel (2004). Strong medicine: creating incentives for pharmaceutical research on neglected diseases. Princeton, N.J.: Princeton Univ. Press. ISBN   978-0-691-12113-0.
  7. ↑ Kvåle, Gunnar (September 2001). "Tackling the diseases of poverty". The Lancet. 358 (9284): 845–846. doi:10.1016/s0140-6736(01)05996-7. ISSN   0140-6736. PMID   11570414.
  8. ↑ Berndt, Ernst R.; Glennerster, Rachel; Kremer, Michael R.; Lee, Jean; Levine, Ruth; Weizsäcker, Georg; Williams, Heidi (2006-10-02). "Advance market commitments for vaccines against neglected diseases: estimating costs and effectiveness". Health Economics. 16 (5) (published May 2007): 491–511. doi:10.1002/hec.1176. ISSN   1057-9230. PMID   17013993. S2CID   10511922.
  9. 1 2 "GAVI partners fulfill promise to fight pneumococcal disease". gavi.org. Archived from the original on 13 January 2011.
  10. ↑ World Health Organization (2007). "Pneumococcal conjugate vaccine for childhood immunization—WHO position paper" (PDF). Weekly Epidemiological Record (12). ISSN   0049-8114.
  11. ↑ Nayar, Anjali (2011-02-11). "Pneumococcal vaccine rolls out in developing world". Nature. doi:10.1038/news.2011.89. ISSN   1476-4687.
  12. ↑ "Pneumonia vaccine price drops dramatically for lower-income countries thanks to the Gavi pneumococcal Advance Market Commitment". India Education | Latest Education News | Global Educational News | Recent Educational News. 2020-06-17. Retrieved 2024-02-16.
  13. ↑ "Supply agreements". www.gavi.org. 2018-06-06. Retrieved 2024-02-16.
  14. ↑ Usher, Ann Danaiya (May 18, 2019). "Low-cost pneumonia vaccine breaks into global market". The Lancet. 393 (10185): 2025–2026. doi:10.1016/s0140-6736(19)31084-0. ISSN   0140-6736. PMID   31106739. S2CID   155105175.
  15. 1 2 3 4 5 Dalberg (15 October 2021). Gavi PCV AMC pilot: 2nd Outcomes and Impact Evaluation (PDF).
  16. ↑ "Access: MSF launches global action against Pfizer and GlaxoSmithKline to cut the price of the pneumonia vaccine | MSF". Médecins Sans Frontières (MSF) International. 12 November 2015. Retrieved 2024-02-16.
  17. ↑ "Gavi should stop awarding special funds to Pfizer and GSK for pneumonia vaccine". Médecins Sans Frontières (MSF) International. 26 August 2019. Retrieved 2024-02-16.
  18. ↑ "Pfizer and GSK should not get huge subsidy for pneumonia vaccine | MSF". Médecins Sans Frontières (MSF) International. 3 December 2019. Retrieved 2024-02-16.
  19. ↑ "Opinion | Advance Market Commitments Worked for Vaccines. They Could Work for Carbon Removal, Too". Politico. 22 December 2021. Retrieved 2022-09-30.
  20. ↑ "An advance market commitment to accelerate carbon removal". frontierclimate.com. Retrieved 2022-09-30.
  21. ↑ Meyer, Robinson (2022-04-13). "We've Never Seen a Carbon-Removal Plan Like This Before". The Atlantic. Retrieved 2022-09-30.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.